![]() | Only 14 pages are availabe for public view |
Abstract Bladder cancer, mostly urothelial carcinoma, is a highly prevalent disease globally and is associated with significant morbidity, mortality and cost (Jemal et al., 2008; Kirkali et al., 2005). urothelial carcinoma of the bladder are classified into two major categories; non muscle invasive and muscle invasive disease (Burger et al., 2013a). Unfortunately, there have been few advances in bladder cancer management due to a poor understanding of the correlations between its molecular and clinical features. Accumulating evidence suggests that bladder cancer represents a group of molecularly and clinicopathologically heterogeneous diseases (Hedegaard et al., 2016; Kim et al., 2015; Robertson et al., 2017). Observed epidemiological differences between males and females are obvious and suggest the potential involvement of sex steroid hormones and their receptors in bladder cancer development and progression (McCahy et al., 1997; Siegel et al., 2012). Recent studies have provided data supporting the hypothesis that AR signaling plays an essential role in the development and progression of bladder cancer (Chen et al., 2003; Kashiwagi et al., 2014; Miyamoto et al., 2007; Shiota et al., 2012). Our study was carried out to investigate the expression of AR in urothelial carcinoma of the bladder and correlate between AR expression and the clinicopathological features of the tumor and the disease outcome. It was descriptive study included 44 of histo¬pathologically confirmed cases of urothelial carcinoma of the bladder treated at our department between (1/1/2010-31/12/2014) and initial pathological diagnosis was done at the Pathology lab of the SCU hospital, where their paraffin blocks are available for the study. Regarding the sociodemographic results, the majority of the patients (86.33%) were males with male to female ratio about (6:1). The mean age of the patients was 64 years. The maximum percentage of the studied patients (80%) came from rural areas. |